Epidemiology of low-grade serous ovarian cancer

American Journal of Obstetrics and Gynecology

Volumn 198, Issue 4, 2008, Pages 459.e1-459.e9

  Plaxe, Steven C ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

descriptive epidemiology; End Results program; Epidemiology; ovarian cancer; Surveillance; tumor grade

Indexed keywords

ADULT; ADVANCED CANCER; ARTICLE; CANCER GRADING; CANCER INCIDENCE; CANCER REGISTRY; CANCER SURVIVAL; EARLY CANCER; EPIDEMIC; FEMALE; HUMAN; OVARY CANCER; POSTMENOPAUSE; PREMENOPAUSE; PRIORITY JOURNAL;

EID: 41349119347     PISSN: 00029378     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajog.2008.01.035     Document Type: Article

References (26)

1. Malpica A., Deavers M.T., Lu K., et al. Grading ovarian serous carcinoma using a two-tier system. Am J Surg Pathol 28 (2004) 496-504
2. Gershenson D.M., Sun C.C., Lu K.H., et al. Clinical behavior of stage II-IV low-grade serous carcinoma of the ovary. Obstet Gynecol 108 (2006) 361-368
3. Jazaeri A.A., Lu K., Schmandt R., et al. Molecular determinants of tumor differentiation in papillary serous ovarian carcinoma. Mol Carcinogen 36 (2003) 53-59
4. Bonome T., Lee J., Park D., et al. Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary. Cancer Res 65 (2005) 10602-10612
5. Speck O., Hughes S.C., Noren N.K., Kulikauskas R.M., and Fehon R.G. Moesin functions antagonistically to the Rho pathway to maintain epithelial integrity. Nature 421 (2003) 83-87
6. Meinhold-Heerlein I., Bauerschlag D., Hilpert F., et al. Molecular and prognostic distinction between serous ovarian carcinomas of varying grade and malignant potential. Oncogene 24 (2005) 1053-1065
7. Singer G., Oldt R., Cohen Y., et al. Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J Natl Cancer Inst 95 (2003) 484-486
8. Singer G., Stohr R., Cope L., et al. Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis. Am J Surg Pathol 29 (2005) 218-224
9. Berchuck A., Iversen E.S., Lancaster J.M., et al. Patterns of gene expression that characterize long-term survival in advanced stage serous ovarian cancers. Clin Cancer Res 11 (2005) 3686-3696
10. Trimble C.L., Kosary C., and Trimble E.L. Long-term survival and patterns of care in women with ovarian tumors of low malignant potential. Gynecol Oncol 86 (2002) 34-37
11. Parazzini F., and La Vecchia C. Epidemiology of adenocarcinoma of the cervix. Gynecol Oncol 39 (1990) 40-46
12. Wang S.S., Sherman M.E., Hildesheim A., Lacey J.V., and Devesa S. Cervical adenocarcinoma and squamous cell carcinoma incidence trends among white women and black women in the United States for 1976-2000. Cancer 100 (2004) 1035-1044
13. Anderson W.F., Jatoi I., and Devesa S.S. Distinct breast cancer incidence and prognostic patterns in the NCI's SEER program: suggesting a possible link between etiology and outcome. Breast Cancer Res Treat 90 (2005) 127-137
14. Moslehi R., Devesa S.S., Schairer, and Fraumeni J.F. Rapidly increasing incidence of ocular non-Hodgkin lymphoma. J Natl Cancer Inst 98 (2006) 936-939
15. Mink P.J., Sherman M.E., and Devesa S.S. Incidence patterns of invasive and borderline ovarian tumors among white women and black women in the United States. Cancer 95 (2002) 2380-2389
16. McGlynn K.A., Devesa S.S., Graubard B.I., and Castle P.E. Increasing incidence of testicular germ cell tumors among black men in the United States. J Clin Oncol 23 (2005) 5757-5761
17. Miettinen O., and Nurminen M. Comparative analysis of two rates. Stat Med 4 (1985) 213-226
18. Ries LAG, Harkins D, Krapcho M, et al, eds. SEER Cancer Statistics Review, 1975-2003. Bethesda (MD): National Cancer Institute. Available at http://seer.cancer.gov/csr/1975_2003. Accessed July 2006.
19. Peto R., and Peto J. Asymptotically efficient rank invariant test procedures. J R Stat Soc B 135 (1972) 185-198
20. Plaxe S.C., and Salzstein S.L. Estimation of the preclinical phase of cervical adenocarcinoma suggests that there is ample opportunity for screening. Gynecol Oncol 75 (1999) 55-61
21. Task Force on Cervical Cancer screening Programs. Epidemiology and natural history of carcinoma of the cervix. Can Med Assoc J 114 (1976) 1003-1012
22. Smith H.O., Tiffany M.F., Qualls C.R., and Key C.R. The rising incidence of adenocarcinoma relative to squamous cell carcinoma of the uterine cervix in the United States-a 24-year population-based study. Gynecol Oncol 78 (2000) 97-105
23. Morabia A., and Flandre P. Misclassification bias related to definition of menopausal status in case-control studies of breast cancer. Int J Epidemiol 21 (1992) 222-228
24. Plaxe S.C., and Salzstein S.L. Impact of ethnicity on the incidence of high-risk endometrial carcinoma. Gynecol Oncol 65 (1997) 8-12
25. Freeman H. Race poverty and cancer. J Natl Cancer Inst 83 (1991) 526-527
26. Shvartsman H.S., Sun C.S., Bodurka D.C., et al. Comparison of the clinical behavior of newly diagnosed stages II-IV low-grade serous carcinoma of the ovary with that of serous ovarian tumors of low malignant potential that recur as low-grade serous carcinoma. Gynecol Oncol 105 (2006) 625-629